Pevonedistat plus azacitidine may increase survival for myelodysplastic syndrome, AML
Original Publication Date
Article Source
External Web Content
Pevonedistat plus azacitidine increased overall survival, event-free survival and response rates compared with azacytidine alone in higher-risk myelodysplastic syndromes and low-blast acute myeloid leukemia, according to data presented at ASCO. (continued at link)
